{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:48:08Z","timestamp":1787014088781,"version":"build-2736575974"},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2017,11,16]],"date-time":"2017-11-16T00:00:00Z","timestamp":1510790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabet. Med."],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>\n                      Glucose\u2010lowering interventions in Type\u00a02 diabetes mellitus have demonstrated reductions in microvascular complications and modest reductions in macrovascular complications. However, the degree to which targeting different HbA\n                      <jats:sub>1c<\/jats:sub>\n                      reductions might reduce risk is unclear.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Participant\u2010level data for Trial Evaluating Cardiovascular Outcomes with Sitagliptin (\n                      <jats:styled-content style=\"fixed-case\">TECOS<\/jats:styled-content>\n                      ) participants with established cardiovascular disease were used in a Type\u00a02 diabetes\u2010specific simulation model to quantify the likely impact of different HbA\n                      <jats:sub>1c<\/jats:sub>\n                      decrements on complication rates. Ten\u2010year micro\u2010 and macrovascular rates were estimated with HbA\n                      <jats:sub>1c<\/jats:sub>\n                      levels fixed at 86, 75, 64, 53 and 42\u00a0mmol\/mol (10%, 9%, 8%, 7% and 6%) while holding other risk factors constant at their baseline levels. Cumulative relative risk reductions for each outcome were derived for each HbA\n                      <jats:sub>1c<\/jats:sub>\n                      decrement.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 5717 participants studied, 72.0% were men and 74.2% White European, with a mean (\n                      <jats:sc>sd<\/jats:sc>\n                      ) age of 66.2 (7.9)\u00a0years, systolic blood pressure 134 (16.9)\u00a0mmHg,\n                      <jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>\n                      \u2010cholesterol 2.3 (0.9)\u00a0mmol\/l,\n                      <jats:styled-content style=\"fixed-case\">HDL<\/jats:styled-content>\n                      \u2010cholesterol 1.13 (0.3)\u00a0mmol\/l and median Type\u00a02 diabetes duration 9.6 (5.1\u201315.6)\u00a0years. Ten\u2010year cumulative relative risk reductions for modelled HbA\n                      <jats:sub>1c<\/jats:sub>\n                      values of 75, 64, 53 and 42\u00a0mmol\/mol, relative to 86\u00a0mmol\/mol, were 4.6%, 9.3%, 15.1% and 20.2% for myocardial infarction; 6.0%, 12.8%, 19.6% and 25.8% for stroke; 14.4%, 26.6%, 37.1% and 46.4% for diabetes\u2010related ulcer; 21.5%, 39.0%, 52.3% and 63.1% for amputation; and 13.6%, 25.4%, 36.0% and 44.7 for single\u2010eye blindness.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      These simulated complication rates might help inform the degree to which complications might be reduced by targeting particular HbA\n                      <jats:sub>1c<\/jats:sub>\n                      reductions in Type\u00a02 diabetes.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dme.13533","type":"journal-article","created":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T03:43:03Z","timestamp":1508730183000},"page":"72-77","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Modelling incremental benefits on complications rates when targeting lower HbA\n                    <sub>1c<\/sub>\n                    levels in people with Type 2 diabetes and cardiovascular disease"],"prefix":"10.1111","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0415-7908","authenticated-orcid":false,"given":"S. A.","family":"Mostafa","sequence":"first","affiliation":[{"name":"Diabetes Trials Unit Oxford Centre for Diabetes Endocrinology and Metabolism"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. L.","family":"Coleman","sequence":"additional","affiliation":[{"name":"Diabetes Trials Unit Oxford Centre for Diabetes Endocrinology and Metabolism"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. F.","family":"Agbaje","sequence":"additional","affiliation":[{"name":"Diabetes Trials Unit Oxford Centre for Diabetes Endocrinology and Metabolism"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Gray","sequence":"additional","affiliation":[{"name":"Nuffield Department of Population Health Health Economics Research Centre University of Oxford"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. R.","family":"Holman","sequence":"additional","affiliation":[{"name":"Diabetes Trials Unit Oxford Centre for Diabetes Endocrinology and Metabolism"},{"name":"Oxford NIHR Biomedical Research Centre Churchill Hospital Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Bethel","sequence":"additional","affiliation":[{"name":"Diabetes Trials Unit Oxford Centre for Diabetes Endocrinology and Metabolism"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,11,16]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1008862"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16895-5"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.317.7160.703"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806470"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414266"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802987"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1470-0"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-127-9-199711010-00003"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.2894"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079903125002611"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-2940-y"},{"key":"e_1_2_9_13_1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12962-015-0038-8","article-title":"Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model","volume":"13","author":"McEwan P","year":"2015","journal-title":"Cost Eff Resourc Alloc"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.01.002"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501352"},{"key":"e_1_2_9_16_1","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.ahj.2013.09.003","article-title":"Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease","volume":"166","author":"Green JB","year":"2013","journal-title":"Am Heart J"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12441"},{"key":"e_1_2_9_18_1","unstructured":"NIH US National Library of Medicine: Medline Plus. Available athttps:\/\/www.nlm.nih.gov\/medlineplus\/ency\/article\/003643.htm. Last accessed 1 April 2016."},{"issue":"1","key":"e_1_2_9_19_1","first-page":"S39","article-title":"American Diabetes Association Standards of Medical Care in Diabetes: Glycemic Targets","volume":"39","year":"2016","journal-title":"Diabetes Care"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(05)70323-6"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2001.00620.x"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2014-000057"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2005.08.010"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203858"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001286"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2014.296"}],"container-title":["Diabetic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdme.13533","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dme.13533","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T03:07:15Z","timestamp":1695611235000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dme.13533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,16]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1111\/dme.13533"],"URL":"https:\/\/doi.org\/10.1111\/dme.13533","archive":["Portico"],"relation":{},"ISSN":["0742-3071","1464-5491"],"issn-type":[{"value":"0742-3071","type":"print"},{"value":"1464-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,16]]},"assertion":[{"value":"2017-10-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}